Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14806825 | 0.95 | CA2 (0.34) | CA2P2RX3 | |
| SCHEMBL17523546 | 0.95 | CA2 (0.34) | CA2P2RX3 | |
| SCHEMBL14820596 | 0.95 | CA2 (0.34) | CA2P2RX3 | |
| SCHEMBL24518381 | 0.93 | CA2 (0.34) | CA2 | |
| SCHEMBL20088485 | 0.92 | CA2 (0.36) | CA2 | |
| SCHEMBL25541258 | 0.92 | CA2 (0.33) | CA2P2RX3 | |
| SCHEMBL17227477 | 0.91 | CA2 (0.33) | CA2 | |
| SCHEMBL21123041 | 0.90 | CA2 (0.35) | CA2P2RX1P2RX3 | |
| SCHEMBL17636632 | 0.90 | CA2 (0.32) | CA2 | |
| SCHEMBL13891880 | 0.89 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230734-B2 | Modified nucleotide linkers | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20190153529-A1 | MODIFIED NUCLEOTIDE LINKERS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153529-A1 | MODIFIED NUCLEOTIDE LINKERS | RNGTT, DTYMK, DPYD | CA2 4550/4885ALDH1A1 2102/4885P2RX1 1221/4885 |
| US-11230734-B2 | Modified nucleotide linkers | RNGTT, DTYMK, DPYD | CA2 4550/4885ALDH1A1 2102/4885P2RX1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.